TY - JOUR
TI - Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: Analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone
AU - Harousseau, J.-L.
AU - Palumbo, A.
AU - Richardson, P.G.
AU - Schlag, R.
AU - Dimopoulos, M.A.
AU - Shpilberg, O.
AU - Kropff, M.
AU - Kentos, A.
AU - Cavo, M.
AU - Golenkov, A.
AU - Komarnicki, M.
AU - Mateos, M.-V.
AU - Esseltine, D.-L.
AU - Cakana, A.
AU - Liu, K.
AU - Deraedt, W.
AU - Van De Velde, H.
AU - San Miguel, J.F.
JO - Blood advances
PY - 2010
VL - 116
TODO - 19
SP - 3743-3750
PB - American Society of Hematology
SN - null
TODO - 10.1182/blood-2010-03-275800
TODO - bortezomib;  melphalan;  prednisone, aged;  article;  controlled study;  drug efficacy;  female;  hazard ratio;  human;  major clinical study;  male;  multiple cycle treatment;  multiple myeloma;  priority journal;  prognosis;  treatment duration;  treatment outcome;  treatment response
TODO - The phase 3 Velcade as Initial Standard Therapy in Multiple Myeloma: Assessment with Melphalan and Prednisone study in newly diagnosed multiple myeloma patients ineligible for high-dose therapy demonstrated that bortezomib-melphalan-prednisone (VMP) was superior to melphalan-prednisone across all efficacy end points. We assessed the prognostic impact of response on time-to-event parameters in the intent-to-treat population. Patients received nine 6-week cycles of treatment. Time to progression, time to next therapy, and treatment-free interval were associated with quality of response. When European Group for Blood and Marrow Transplantation criteria were used, complete response (CR) was associated with significantly longer time to progression (hazard ratio [HR] = 0.45, P = .004), time to next therapy (HR = 0.46, P = .0004), and treatment-free interval (HR = 0.38, P < .0001) versus partial response, but there was no significant difference in overall survival (HR = 0.87, P = .54); similar differences were seen with CR versus very good partial response by uniform criteria. Quality of response improved with prolonged VMP treatment, with 28% of CRs achieved during cycles 5-9. CR duration appeared similar among patients with "early" (cycles 1-4) and "late" CRs (cycles 5-9) and among patients receiving 9 versus < 9 cycles of bortezomib within VMP. These results highlight that CR is an important treatment goal and support prolonged VMP therapy to achieve maximal response. This study is registered at http://www.clinicaltrials.gov as NCT00111319. © 2010 by The American Society of Hematology.
ER -